1. Houston,
K., Aldridge, K., and Magee,
L., 1975. The effect of R antigen
on the attachment of Bdellovibrio bacteriovorus to Salmonella typhimurium.
Acta Microbiologica Polonica. 6:253-255.
2. Aldridge,
K.E., 1975. Growth and cytopathology of Mycoplasma
synoviae in chicken embryo cell
cultures. Infect. Immunity, 12:198-204.
3. Aldridge,
K.E., Cole, B.C., and Ward,
J.R., 1977. Mycoplasma-activation
of normal lymphocytes. 1.
Induction of a lymphocyte-mediated cytotoxicity for allogeneic and syngeneic
mouse target cells. Infect.
Immunity, 18:377-385.
4. Aldridge,
K.E., Cole, B.C., and Ward, J.R.,
1977. Mycoplasma-dependent
activation of normal lymphocytes.
2. The role of arginine and non-viable mycoplasma antigen in the
induction of lymphocyte-mediated cytotoxicity for syngeneic mouse target
cells. Infect. Immunity, 18:386-392.
5. Cole,
B.C., Aldridge, K.E., and
Ward, J.R., 1977.
Mycoplasma-dependent activation of normal lymphocytes. 3. Mitogenic potential of mycoplasmas
for mouse lymphocytes. Infect.
Immunity, 18:393-399.
6. Aldridge,
K.E., and Cole, B.C., 1978. Immunofluorescent and electron
microscopic examination of the attachment of Mycoplasma synoviae to chick embryo cells. Infect. Immunity, 21:328-332.
7. Aldridge,
K.E., Gardner, B.B., Clark, S.,
and Matsen, J.M., 1978. A
comparison of the Micro-ID, API-20E, and conventional media systems in the
identification of Enterobacteriaceae. J. Clin. Micro. 7:507-513.
8. Cole,
B.C., Aldridge, K.E., and
Ward, J.R., 1980.
Mycoplasma-dependent activation of normal mouse lymphocytes: Requirements for functional lymphocytes
in the cytotoxicity reaction mediated by Mycoplasma arthritidis.
Infect. Immunity, 30:90-98.
9. Aldridge,
K.E., and Hodges, R.L.,
1981. Identification of Enterobacteriaceae: Comparison of Enteroset 20, API-20E, and
conventional systems. J. Clin.
Microbiol. 13:129-125.
10. Marier,
R.L., Faro, S., Sanders, C.V., Williams, W., Derks, F., and Aldridge, K.E., 1982.
Moxalactam in the therapy of serious infections. Antimicrob. Agents. Chemother. 3:161-164.
11. Aldridge,
K.E., 1982. Coagulase-negative staphylococcal infections
in humans. Infection Control, 3:161-164.
12. Marier,
R.L., Marianaccio, A.T., Sanders, C.V., Aldridge, K.E., and Mitchell, J.W., 1982. Susceptibility patterns of bacteria
following therapy with piperacillin. J. Antimicrob. Chemother. 9:(Suppl.
B):85-91.
13. Faro,
S., Sanders, C.V., and Aldridge, K.E., 1982. Use of single
agent antimicrobial therapy in the treatment of polymicrobial female pelvic
infections (comparison of ticarcillin, chloramphenicol, and clindamycin). J.
Obstetrics Gynecol. 60:232-236.
14. Sanders,
C.V., Aldridge, K.E., and
Marier, R.L., 1982. Diagnosis of
anaerobic infections. In:
Proceedings of the First United States Metronidazole Conference. Tarpon Springs, Florida. Biomedical Information Corporation. pp. 11-23.
15. Marier,
R.L., Aldridge, K.E., and
Sanders, C.V., 1982. The role of
anaerobes in sinus and middle ear infections--implications for the future. In: Proceedings of the First United States Metronidazole
Conference. Tarpon Springs,
Florida. Biomedical Information
Corporation. pp. 357-369.
16. Marier,
R.L. Sanders, C.V., Faro, S., Williams, W., Derks, F., and Aldridge, K.E., 1982.
Piperacillin versus carbenicillin in the therapy of serious
infections. Archives of Internal
Medicine. 42(Suppl.):2000-2005.
17. Aldridge,
K.E., Stratton, C.W., and
Patterson, L.S., Evans, M.E., and Hodges, R.L., 1983. Comparison of the API Staph-Ident System with a conventional
method for identification of urine and blood isolates of coagulase negative
staphylococci. J. Clin. Microbiol.
17:516-520.
18. Tally,
F.P., Cuchural, G.J., Jacobus, N.V., Gorbach, S.L., Aldridge, K.E., Cleary, T.J., Finegold, S.M., Hill, G.B.,
Iannini, P.B., McCloskey, R.V., O'Keefe, J.P., and Pierson, C.L., 1983. A survey of the susceptibility of Bacteroides
fragilis group in the United
States in 1981. Antimicrob. Agents
Chemother. 23:536-540.
19. Aldridge,
K.E., Sanders, C.V., Marier,
R.L., and Lewis, A.C., 1983.
Studies on the susceptibility of anaerobic bacteria to beta-lactam
antibiotics and beta-lactamase production. J. Med. Micro. 16:75-82.
20. Faro,
S., Pastorek, J.P., and Aldridge, K.E., 1983. Treatment of
gram-negative infections with penicillins. Proceedings of the 13th International Congress of
Chemotherapy, Vienna, Austria, pp. 52-58.
21. Aldridge,
K.E., Sanders, C.V., Faro, S.,
and Marier, R.L., 1983. Comparison
of the in vitro activity of azlocillin and mezlocillin with other antibiotics
against clinical isolates of Bacteroides fragilis, B. melaninogenicus, and B. bivius.
Proceedings of the 13th International Congress of Chemotherapy, Vienna,
Austria, pp. 38-43.
22. Marier,
R.L,. MacCloskey, R.V., Dickinson, G., Sanders, C.V., Hoffman, T., Gutterman,
D., and Aldridge, K.E.,
1983. Comparative clinical trial
of N-formimidoylthienamycin-dehydropeptidase inhibitor (MK0787/0791) and
cefazolin. Proceedings of the 13th
International Congress of Chemotherapy, Vienna, Austria, pp. 23-29.
23. Sanders,
C.V. and Aldridge, K.E.,
1983. The microbiology
laboratory: garbage in, garbage
out. Clin. Microbiol. Newsletter 5:123-125.
24. Aldridge,
K.E., Janney, A., Sanders, C.V.,
and Marier, R.L., 1983.
Interlaboratory variation of antibiograms of methicillin-resistant and
methicillin-sensitive Staphylococcus aureus using conventional and commercial testing
systems. J. Clin. Micro. 18:1226-1236.
25. Marier,
R.L., McCloskey, R.V., Dickinson, G., Sanders, C.V., Aldridge, K.E., Hoffman, T., Gutterman, D., and Janney, A.,
1983. Comparative clinical trial
of imipenem - cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor)
and cefazolin. J. Antimicrob. Chemother. 12(Suppl.D):133-139.
26. Faro,
S., Pastorek, J.G., Plauche, W.C., Korndorffer, F.A., and Aldridge, K.E., 1984. Short-course parenteral antibiotic
therapy for pyelonephritis in pregnancy.
Southern Med. J. 77:455-457.
27. Shoji,
H., Gutierrez, M.M., and Aldridge, K.E., 1984. The use of 2%
glutaraldehyde as a disinfectant for arthroscopes used in septic joints. Orthopedics 7:241-244.
28. Aldridge,
K.E., Kogos, C., Sanders, C.V.,
and Marier, R.L., 1984. Comparison
of rapid identification assays for Staphylococcus aureus. J.
Clin. Microbiol. 19:703-704.
29. Aldridge,
K.E., 1984. Monograph: Laboratory parameters
regarding isolation and identification of anaerobic bacteria. A publication of Marion Scientific,
Kansas City, MO.
30. Aldridge,
K.E., Sanders, C.V., and Marier,
R.L., 1984. In vitro synergy and
potentiation between cefotaxime and desacetylcefotaxime against clinical
isolates of Bacteroides. Diagn. Microbiol. Infect. Dis. 2:475-535.
31. Cuchural,
G.J., Jr., Tally, F.P., Jacobus, N.V., Gorbach, S.L., Aldridge, K.E., Cleary, T., Finegold, S.M., Hill, G., Iannini,
P., O'Keefe, J.P., and Pierson, C., 1984. Antimicrobial susceptibilities of
1,292 isolates of the Bacteroides fragilis group in the United States: Comparison of 1981 with 1982. Antimicrob. Agents Chemother. 26:145-148.
32. Aldridge,
K.E., Sanders, C.V., Janney, A.,
Faro, S., and Marier, R.L., 1984.
Comparison of the activities of penicillin G and new ß-lactam
antibiotics against clinical isolates of Bacteroides species.
Antimicrob. Agents Chemother. 26:410-413.
33. Pastorek,
J.G., Cole, C., Aldridge, K.E.,
and Crapanzano, J.C., 1985.
Aztreonam plus clindamycin as therapy for pelvic infections in women. Am. J. Med. 78(Suppl 2A):47-50.
34.
Aldridge, K.E., Schiro, D., Tsai, L., Janney, A., Sanders,
C.V., and Marier, R.L., 1985. Ciprofloxacin (BAY o 9867): An in vitro
comparison with other
broad-spectrum antibiotics. Curr.
Ther. Res. 37:754-762.
35. Aldridge,
K.E., 1985. Methicillin-resistant Staphylococcus
aureus: clinical and laboratory features. Infect. Control, 6:461-465.
36. Tally,
F.P., Cuchural, G.J., Jr., Jacobus, N.V., Gorbach, S.L., Aldridge, K.E., Cleary, T., Finegold, S.M., Hill, G., Iannini,
P., O'Keefe, P., and Pierson, C., 1985.
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob. Agents
Chemother. 28:675-677.
37. Aldridge,
K.E., Janney, A., and Sanders,
C.V., 1985. Comparison of the
activities of coumermycin, ciprofloxacin, teicoplanin, and other non-ß-lactam
antibiotics against clinical isolates of methicillin-resistant Staphylococcus
aureus from various geographical
locations. Antimicrob. Agents Chemother. 28:634-638.
38. Sanders,
C.V., Marier, R.L., Aldridge, K.E., Derks, F.W., and Martin, D.H., 1985. Safety and effectiveness of ticarcillin plus clavulanic acid
in the treatment of community-acquired pyelonephritis in adult women. Amer. J. Med. 79:(Suppl
5B):96-100.
39. Pastorek,
J.G. Jr., Aldridge, K.E.,
Cunningham, G.L., Faro, S., Graffeo, S., McNealey, G.S., and Tan, J.S.,
1985. Comparison of ticarcillin
plus clavulanic acid with cefoxitin in the treatment of female pelvic
infections. Amer. J. med. 79(Suppl
5B):161-163.
40. Aldridge,
K.E., 1985. The new fluorinated 4-quinolone
antibiotics. Mediguide to
Infectious Diseases, 5:1-6.
41. Aldridge,
K.E., and Sanders, C.V.,
1985. Increased in vitro anti-Bacteroides
activity of cefotaxime: Synergistic interaction of cefotaxime and desacetylcefotaxime. Recent Advances in Chemotherapy. Proceedings of the 14th International
Congress of Chemotherapy, Kyoto, Japan,
pp. 606-607.
42. Aldridge,
K.E., Tsai, L., and Sanders,
C.V., 1985. Comparative activity
of ciprofloxacin (BAY o 9867) with beta-lactam antibiotics and gentamicin, and
the effect of inoculum size, against aerobic gram-positive and negative
bacteria. Recent Advances in
Chemotherapy. Proceedings of the
14th International Congress of Chemotherapy, Kyoto, Japan, pp.1559-1560.
43. Aldridge,
K.E., Sanders, C.V., and Marier,
R.L., 1986. Variation in the
potentiation of beta-lactam antibiotic activity by clavulanic acid and
sulbactam against multiple antibiotic-resistant bacteria. J. Antimicrob. Chemother. 17:463-469.
44. Pastorek,
J.G., II, Faro, S., Aldridge, K.E., Graffeo, S., and McKenna, C.C., 1986. Imipenem as a single-agent antibiotic therapy for
postcesarean infection. Curr.
Therapeutic Res. 40:225-231.
45. Zide,
M.F., Sanders, C.V., Marier, R.L., Aldridge, K.E., and Derks, F.W., 1986. Cefuroxime therapy for maxillofacial
infections. Curr. Therapeutic Res.
40:278-287.
46. Aldridge,
K.E. and Sanders, C.V.,
1986. Comparison of the activity
of carumonam (RO 17-2301) with other broad-spectrum antibiotics: In vitro antibacterial spectrum,
inoculum effect, and synergy studies.
Curr. Therapeutic Res. 40:515-527.
47. Aldridge,
K.E. and Sanders, C.V.,
1986. Comparison of the activity
of cefpirome (HR 810) , a new cephalosporin, to other beta-lactams against clinical
isolates of Streptococcus agalactiae. Curr. Therapeutic Res. 40:1069-1077.
48. Aldridge,
K.E., Schiro, D.D., and Sanders,
C.V., 1986. Pefloxacin (RB 1589):
an in vitro comparison with other oral antimicrobial agents and imipenem. Curr. Therapeutic Res. 40:1103-1113.
49. Stratton,
C.W., Weeks, L.S., and Aldridge, K.E., 1987. Comparison of
kill-kinetic studies with agar and broth microdilution methods for
determination of antimicrobial activity of selected agents against members of
the Bacteroides fragilis
group. J. Clin. Microbiol. 25:645-649.
50. Aldridge,
K.E., Sanders, C.V., and Marier,
R.L., 1987. Correspondence: Determining the MIC's of ß-lactams for Haemophilus. J.
Antimicrob. Chemother. 19:551-552.
51. Aldridge,
K.E., Schiro, D.D., and Sanders,
C.V., 1987. Comparative in vitro
activity of the new oral cephalosporin BMY-28100. Eur. J. Clin. Microbiol. 6:170-172.
52. Aldridge,
K.E., Schiro, D.D., and Sanders,
C.V., 1987. RO 23-6240, A new
orally absorbed quinolone: In
vitro comparison with other broad-spectrum oral antimicrobial agents and
imipenem. Diag. Microbiol. Infect.
Dis. 7:9-19.
53. Pastorek,
J.G. II, Faro, S., Aldridge, K.E., and Nicaud, S.K.,
1987. Moxalactam versus
clindamycin plus tobramycin for the treatment of puerperal infections. Southern Med. J. 80:1116-1119.
54. Faro,
S., Pastorek, J.G., Aldridge, K.E., Martens, M., Phillips, L.E., Nicaud, S., and Cunningham, G.,
1987. Piperacillin versus
clindamycin plus gentamicin in the treatment of postpartum endometritis. Curr. Therapeutic Res. 42:995-1002.
55. Aldridge,
K.E., 1987. Controversies in susceptibility testing
of anaerobes. Clin. Therapeutics. 10(Suppl.
A):2-11.
56. Aldridge,
K.E., Schiro, D.D., and Sanders,
C.V., 1987. Comparative in vitro
activity of the two new oral cephalosporin metabolities RO 19-5247 and RO
15-8074. Eur. J. Clin. Microbiol. 6:564-569.
57. Aldridge,
K.E. and Sanders, C.V.,
1987. Antibiotic and
method-dependent variation in susceptibility testing results of Bacteroides fragilis group isolates. J. Clin. Microbiol. 25:2317-2321.
58. Jones,
R.N., Barry, A.L., Aldridge, K.E., and Gerlach, E.H., 1987.
Comparative antimicrobial activity of aminothiazolymethoxyimino
cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant
isolates. Diagn. Microbiol.
Infect. Dis. 8:157-163.
59. Aldridge,
K.E., and Sanders, C.V.,
1988. Pefloxacin, a new
fluorinated quinolone: comparison of its in vitro activity with that of other broad spectrum antibiotics. Rev. Infect. Dis. 10:(Suppl.
1):S40-S41.
60. Aldridge,
K.E., and Sanders, C.V.,
1988. Comparative in vitro
activity of ciprofloxacin, norfloxacin, ofloxacin, ß-lactam antibiotics, and
gentamicin against aerobic gram-positive cocci and gram-negative bacilli. Rev. Infect. Dis. 10(Suppl.
1):S42.
61. Fuchs,
P.C., Jones, R.N., Barry, A.L., Allen, S.D., Aldridge, K.E., Gerlach, E.H., and Sommers, H.M., 1988. Effect of clavulanic acid on the
susceptibility of clinical anaerobic bacteria to ticarcillin: A multicenter
study. Diagn. Microbiol. Infect.
Dis. 9:47-50.
62. Cuchural,
G.J., Jr., F.P. Tally, N.V. Jacobus, Aldridge, K.E., T. Cleary, S.M. Finegold, G. Hill, P. Iannini,
J.P. O'Keefe, C. Pierson, D. Crook, T. Russo, and D. Hecht. 1988. Susceptibility of the Bacteroides
fragilis group in the United
States: Analysis by site of isolation.
Antimicrob. Agents Chemother. 32:717-722.
63. Sanders,
C.V., Pastorek, J.G., Miller, J.M., and Aldridge, K.E., 1988.
Ticarcillin disodium and clavulanate potassium in the treatment of
post-cesarean-section endomyometritis. J. Reproduct. Med. 33:584-587.
64. Aldridge,
K.E., Valainis, G.T., and
Sanders, C.V., 1988. Comparison of
the in vitro activity of ciprofloxacin and 24 other antimicrobial agents
against clinical strains of Chromobacterium violaceum.
Diagn. Microbiol. Infect. Dis. 10:31-39.
65. Barry,
A.L., Aldridge, K.E., Allen,
S.D., Fuchs, P.C., Gerlach, E.H., Jones, R.N., and Pfaller, M.A., 1988. In vitro activity of FCE 22101,
imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality
control limits of FCE 22101. Eur.
J. Clin. Microbiol. Dis. 7:794-798.
66. Aldridge,
K.E., Henderberg, A., Schiro,
D.D., and Sanders, C.V., 1988.
Susceptibility of Bacteroides fragilis group isolates to broad-spectrum ß-lactams, clindamycin,
and metronidazole: Rates of resistance, cross-resistance, and importance of
ß-lactamase production. Adv.
Therapy 5:273-282.
67. Jones,
R.N., Aldridge, K.E., Barry,
A.L., Fuchs, P.C., Gerlach, E.H., Pfaller, M.A., and Washington, J.A. II, 1988. Multicenter in vitro evaluation of
lomefloxacin (NT-198, SC-47111), including tests against nearly 7,000 bacterial
isolates and preliminary recommendations for susceptibility testing. Diagn. Microbiol. Infect. Dis. 10:221-240.
68. Fuchs,
P.C., Barry, A.L., Jones, R.N., and Aldridge, K.E., 1989. An in vitro evaluation of HRE 664, a novel penem
antibiotic. Diagn. Microbiol.
Infect. Dis. 11:29-40.
69. Jones,
R.N., Aldridge, K.E., Allen,
S.D., Barry, A.L., Fuchs, P.C., Gerlach, E.H., and Pfaller, M.D., 1989. Multicenter in vitro evaluation of
SM-7338, a new carbapenem.
Antimicrob. Agents Chemother. 33:562-565.
70. Aldridge,
K.E., 1989. Comparison of the in vitro action and
interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp. Diagn. Microbiol. Infect. Dis. 12:45-50.
71. Aldridge,
K.E., Weeks, L.S., Stratton,
C.W., and Sanders, C.V., 1989.
Comparison of the bactericidal activity of cefotaxime and
desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms. Diagn. Microbiol. Infect. Dis. 11(Suppl. 5):S935.
72. Aldridge,
K.E., Henderberg, A., and
Sanders, C.V., 1989. In vitro
activity of lomefloxacin against gram-positive and gram-negative bacteria. Rev. Infect. Dis. 11(Suppl.
5):S935.
73. Aldridge,
K.E., Henderberg, A., and
Sanders, C.V., 1989. Mutational
frequency of gram-positive and gram-negative bacteria to resistance to
lomefloxacin and other quinolones.
Rev. Infect. Dis. 11(Suppl.5):S974-S975.
74. Aldridge,
K.E., Henderberg, A., Gebbia,
K., Schiro, D.D., Janney, A., and Sanders, C.V., 1989. Lomefloxacin, a new fluoroquinolone:
Studies on in vitro antimicrobial spectrum, potency, and development of
resistance. Diagn.
Microbiol. Infect. Dis. 12:221-223.
75. Aldridge,
K.E., Henderberg, A., and
Sanders, C.V., 1989. Lomefloxacin (SC 47111 or NY - 198), a new difluorinated
quinolone: Comparison of the in vitro activity with other broad spectrum
antimicrobials against Enterobacteriaceae, Acinetobacter spp., Aeromonas spp., and Pseudomonas aeruginosa.
Diagn. Microbiol. Infect. Dis. 12(Suppl.):1S-6S.
76. Jones,
R.N., Pfaller, M.A., Fuchs, P.C., Aldridge, K.E., Allen, S.D., and Gerlach, E.H., 1989. Piperacillin/tazobactam (YTR 830)
combination: Comparative antimicrobial activity against 5889 recent aerobic
clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12:489-494.
77. Aldridge,
K.E., Wexler, H., Sanders, C.V.,
and Finegold, S.M., 1990. Comparison of in vitro antibiograms of Bacteroides
fragilis group isolates: Difference in resistance rates in two
institutions because of differences in susceptibility testing methodology. Antimicrob. Agents Chemother. 34:179-181.
78. Aldridge,
K.E., Henderberg, A., Schiro,
D.D., and Sanders, C.V., 1990.
Discordant results between the broth disk elution and broth
microdilution susceptibility tests with Bacteroides fragilis group isolates. J. Clin. Microbiol. 28:375-378.
79. Barry,
A.L., Fuchs, P.C., Gerlach, E.H., Allen, S.D., Acar, J.F., Aldridge, K.E., Bourgault, A.M., Grimm, H., Hall, G.S.,
Heizmann, W., Jones, R.N., Swenson, J.M., Thornsberry, C., Wexler, H.,
Williams, J.D., and Wüst, J., 1990.
Multilaboratory evaluation of an agar diffusion disk susceptibility test
for rapidly growing anaerobic bacteria.
Rev. Infect. Dis. 12(Suppl. 2):210-217.
80. Aldridge,
K.E., Henderberg, A., and
Sanders, C.V., 1990.
Susceptibility of cefoxitin-resistant Bacteroides fragilis group strains to other beta-lactam and
non-beta-lactam antimicrobials. Adv.
Therapy 7:16-21.
81. Aldridge,
K.E., Henderberg, A., and
Sanders, C.V., 1990. Enhanced
antimicrobial activity of old and new ß-lactams against cefoxitin-resistant Bacteroides
fragilis group isolates by
ß-lactamase inhibitors. J.
Antimicrob. Chemother. 25:873-883.
82. Sanders,
C.V. and Aldridge, K.E.,
1990. In vitro anaerobic data on
ticarcillin/clavulanate: A review
of an ongoing survey. J.
Reproductive Med. 35:313-316.
83. Aldridge,
K.E., 1990. An update on the in vitro activity of
ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against
clinically significant anaerobic bacteria. Clinical Therapeutics 12(Suppl. C):3-12.
84. Aldridge,
K.E., Weeks, L.S., Stratton,
C.W., and Sanders, C.V., 1990.
Differences in the in vitro inhibitory and bactericidal activity of
ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides
fragilis group isolates. Comparison of time-kill kinetic studies
with MIC values. Diagn. Microbiol.
Infect. Dis. 13:311-316.
85. Aldridge,
K.E., Henderberg, A., and
Sanders, C.V., 1990. In vitro
study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides
fragilis group strains to
various other antimicrobial agents.
J. Antimicrob. Chemother. 26:353-359.
86. Jones,
R.N., Pfaller, M.A., Allen, S.D., Gerlach, E.H., Fuchs, P.C., and Aldridge,
K.E., 1991. Antimicrobial activity of
cefpirome. An update compared to
five third-generation cephalosporins against nearly 6,000 recent clinical
isolates from five medical centers.
Diagn. Microbiol. Infect. Dis. 14:361-364.
87. Sanders,
C.V. and Aldridge, K.E., 1991.
Antimicrobial therapy of anaerobic infections. Pharmacotherapy. 11(2 Pt. 2): 72S-79S.
88. Karam,
G.H., Sanders, C.V., and Aldridge, K.E., 1991. Role of newer
antimicrobial agents in the treatment of mixed aerobic and anaerobic
infections. Surgery Gynecology
& Obstetrics. 172: (Suppl.) 57-64.
89. Stratton,
C.W., Weeks, L.S., and Aldridge, K.E., 1991. Comparison of the
bactericidal activity of clindamycin and metronidazole against
cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides
fragilis group. Diagn. Microbiol. Infect. Dis. 14:377-382.
90. Aldridge,
K.E. and Stratton, C.W.,
1991. Bactericidal activity of
ceftizoxime, cefotetan, and clindamycin against cefoxitin-resistant strains of
the Bacteroides fragilis
group. J. Antimicrob. Chemother. 28:701-705.
91. Aldridge,
K.E. and Schiro, D.D.,
1991. In vitro study of potential
synergy of fleroxacin and metronidazole against mixed aerobes and
anaerobes. Eur. J. Clin.
Microbiol. Infect. Dis. (Special Issue), pp. 439-441.
92. Aldridge,
K.E. and Schiro, D.D.,
1991. Fluoroquinolone-oxacillin
resistant Staphylococcus aureus:
An in vitro study of
susceptibility to other antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. (Special Issue), pp.
522-523.
93. Aldridge,
K.E., 1992. In vitro susceptibility of Bacteroides
fragilis group strains from
abscesses, body fluids and wound/tissue sources. Drug Investigation 4:(Suppl. 1):1-6.
94. Aldridge,
K.E., 1992. In vitro antistaphylococcal activities
of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with
those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class
antimicrobial agents.
Antimicrobial Agents and Chemother. 36:851-853.
95. Aldridge,
K.E., Schiro, D.D., and Varner,
L.M., 1992. In vitro
antistaphylococal activity and testing of RP 59500, a new streptogramin, by two
methods. Antimicrob. Agents and
Chemother. 36:854-855.
96. Steinemann,
T.L., Kaufman, H.E., Beuerman, R.W., Varnell, E.D., Thompson, H.W., and Aldridge,
K.E., 1992. Vancomycin-enriched corneal storage
medium. Amer. J. Ophthal. 113:555-560.
97. Stratton,
C.W., Weeks, L., and Aldridge, K.E., 1992. Inhibitory and
bactericidal activity of selected ß-lactam agents alone and in combination with
ß-lactamase inhibitors compared with that of cefoxitin and metronidazole
against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides
fragilis group. Diagn. Microbiol. Infect. Dis. 15:321-330.
98. Aldridge,
K.E., Jones, R.N., Barry, A.L.,
and Gelfand, M.S., 1992. In vitro
activity of various antimicrobial agents against Staphylococcus aureus.
Diagn. Microbiol. Infect. Dis. 15:517-521.
99. Aldridge,
K.E., Gelfand, M.S., Schiro,
D.D., and Barg, N.L., 1992. The
rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus
aureus infections in a community
hospital. Diagn. Microbiol.
Infect. Dis. 15:601-608.
100. Schiro,
D.D. and Aldridge, K.E.,
1992. Broth microdilution
susceptibility testing of anaerobic bacteria. H. Isenberg (ed.), Clinical Microbiology Procedures
Handbook. American Society for Microbiology, Washington, D.C. 5.6.1-5.6.17.
101. Aldridge, K.E., 1992. Antianaerobic activity of various
antimicrobial agents against beta-lactamase-positive and -negative strains of
the Bacteroides fragilis group.
Current Therapeutic Research 52:593-599.
102. Aldridge, K.E., 1992. Cross-resistance to
cephalosporin/cephamycin agents among the Bacteroides fragilis group. Advances in Therapy 9:265-270.
103. Sanders,
C.V. and Aldridge, K.E., 1992.
Current antimicrobial therapy of anaerobic infections. Eur. J. Clin. Microbiol.
Infect. Dis. 11:999-1011.
104. Aldridge, K.E., 1993. A new potent ß-lactamase inhibitor,
BRL-42715, with inherent activity against Bacteroides fragilis group strains. Clin. Infect. Dis. 16
(Suppl 4):S335-S338.
105. Sapico,
F.L. and Aldridge, K.E.,
1993. What important problems remain in the areas of anaerobic bacteriology and
anaerobic infections? Clin. Infect. Dis. 16(Suppl 4):S451-S452.
106. Marier,
R.L., Sanders, C.V., and Aldridge, K.E., 1993. Treatment of polymicrobial infections. Complications in Surg. 12
(Suppl A):S70-S76.
107. Aldridge, K.E., 1993. Antimicrobial susceptibility of relatively
infrequent isolates of the Bacteroides fragiis group: Bacterodies uniformis, Bacteroides
caccae, and Bacteroides eggerthii.
Curr. Therapeutic Res. 54:208-213.
108. Aldridge, K.E., Cammarata, C., and Martin, D. H., 1993. Comparison of the in vitro activities
of various parenteral and oral antimicrobial agents against endemic Haemophilus
ducreyi. Antimicrob. Agents and Chemotherapy, 37:1986-1988.
109. Aldridge, K.E., 1993.
Cross-resistance to ß-lactam — ß-lactamase inhibitor combinations and
clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides
fragilis group. Diagn. Microbiol. Infect. Dis., 17:251-256.
110. Aldridge, K.E., 1993.
Early susceptibility test results with the Bacteroides fragilis group.
J. Antimicrob. Chemother., 32:910-912.
111. Aldridge, K.E., 1994.
In vitro activity of biapenem (L-627), a new carbapenem, against
anaerobes. Antimicrob. Agents and
Chemotherapy, 38:889-893.
112. Aldridge, K.E., 1993.
Activity of ß-lactam—ß-lactamase inhibitor combinations against the Bacteroides
fragilis group: Increased resistance among B.
distasonis strains. Recent Advances in Chemotherapy. Proceedings of the 18th International
Congress of Chemotherapy, Stockholm, Sweden. pp. 478-479.
113. Aldridge, K.E. and Schiro, D.D., 1994. Anaerobic susceptibility testing: Slight differences in inoculum size can
make a difference in minimum inhibitory concentrations. Diagn. Microbiol.
Infect. Dis., 18:191-195.
114. Aldridge, K.E.,
Gelfand, M., Reller, L.B., Ayers, L.W., Pierson, C.L., Schoenknecht, F.,
Tilton, R.C., Wilkins, J., Henderberg, A., Schiro, D.D., Johnson, M., Janney,
A., and Sanders, C.V., 1994.
A five-year multicenter study of the susceptibility of the Bacteroides
fragilis group isolates to
cephamycins, penicillins, clindamycin, and metronidazole in the United
States. Diagn. Microbiol. Infect.
Dis., 18:235-241.
115. Aldridge, K.E., 1994.
Increased activity of a new chlorofluoroquinolone, BAY y 3118,
compared with activities of ciprofloxacin, sparfloxacin, and other
antimicrobial agents against anaerobic bacteria. Antimicrob. Agents
Chemother. 38:1671-1674.
116. Aldridge, K.E., 1994.
Anaerobes in polymicrobial surgical infections: Incidence, pathogenicity, and
antimicrobial resistance. Eur J Surg;
Suppl 573: 31-37.
117. Aldridge, K.E., Morice, N., and Schiro, D.D., 1994. Increased in vitro activity of
ceftriaxone by addition of tazobactam against clinical isolates of
anaerobes. Diagn. Microbiol. Infect.
Dis., 19:227-234.
119. 118. Aldridge,
K.E., and Schiro, D.D.,
1994. Major methodology-dependent
discordant susceptibility results for Bacteroides fragilis group isolates but not other anaerobes. Diagn. Microbiol. Infect. Dis., 20:135-142.
Aldridge, K.E., 1995. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial
infections. The Am. J. of Surg., 169
(Suppl 5A): 2S-7S.
120. Marshall,
S.A., Aldridge, K.E., Allen,
S.D., Fuchs, P.C., Gerlach, E.H., and Jones, R. N. 1995.
Comparative antimicrobial activity of piperacillin-tazobactam tested
against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years. Diagn. Microbiol. Infect. Dis., 21:153-168.
122. 121. Stratton,
C.W., Aldridge, K.E., and
Gelfand, M.S. 1995. In vitro killing of penicillin-susceptible,
-intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime: A comparison of bactericidal and inhibitory activity with
achievable CSF levels. Diagn.
Microbiol. Infect. Dis., 22:35-42. Aldridge, K.E., 1995. Cefotaxime
in the treatment of staphylococcal infections: Comparison of in vitro and in
vivo studies. Diagn. Microbiol.
Infect. Dis., 22:195-201.
123. Aldridge,
K.E., Ashcraft, D., and Bowman, K.A. 1997.
Comparative in vitro activities of trovafloxacin (CP 99,219) and other
antimicrobials against clinically significant anaerobes. Antimicrob. Agents Chemother. 41:484-487.
125. 124. Aldridge,
K.E., and Ashcraft, D. 1997. Comparison of the in vitro activities of Bay12-8039, a new
quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:709-711. Aldridge, K.E., and Johnson, W.D. 1997. A comparison of susceptibility results
of the Bacteroides fragilis
group and other anaerobes by traditional MIC results and statistical
methods. J.
Antimicrob. Chemother. 39:319-324.
126. Aldridge, K.E.
1997. Intra-abdominal
infections: Microbiologic
considerations. Antibiotics
for Clinicians. 1(Suppl 1): 5S-8S.
127. Saenz, R.E., Sanders, C.V., Aldridge, K.E., and Patel, M.M. 1998. Purulent pericarditis with associated cardiac
tamponade caused by a Streptococcus pneumoniae strain highly resistant to penicillin,
cefotaxime, and ceftriaxone. Clin.
Infect. Dis. 26:762-763.
128. Aldridge, K.E. Ashcraft, D.S., and Sanders, C.V. 1998. Trovafloxacin (CP 99,219), a new azabicyclo-naphthyridone
antimicrobial: inhibitory and
bactericidal activity against clinical isolates of penicillin-susceptible and
-resistant Streptococcus pneumoniae. Adv. Ther. 15:65-74.
129. Aldridge, K.E., Ashcraft, D.S., O’Cain, P., Sanders, C.V.,
Janney, A., Brown, W., Silbermann, R., and Pankey, G. 1998. A
multicenter study of the prevalence and susceptibility patterns of isolates of Streptococcus
pneumoniae with reduced
susceptibility to penicillin G in Louisiana. Amer. J. Med. Sci.
316:277-284.
130. Aldridge,
K.E., Ashcraft, D.S. and
Sanders, C.V. 1998. RP 59,500 (Quinupristin/Dalfopristin): A new streptogramin with potent
activity against penicillin-resistant
Streptococcus pneumoniae. Adv. Ther. 15:158-164.
131. Aldridge,
K.E., Ashcraft, D., Cambre, K.,
Pierson, C.L., Jenkins, S.G., and Rosenblatt,
J.E. 2001. Comparison of the changing in vitro
antimicrobial susceptibility of
clinical isolates of the B. fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
Antimicrob. Agents Chemother. 45:1238-1243.
132. Aldridge,
K.E. 2002. Ertapenem
(MK-0826), a new carbapenem:
comparative in vitro activity
against clinically significant anaerobes.
Diagn. Microbiol. Infect.
Dis. 44:181- 186 .
133. Aldridge,
K.E. and O’Brien, M. 2002. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall
susceptibility data. J. Clin.
Microbiol. 40:4349-4352.
134. Aldridge,
K.E. 2002. Comparison of the post-antibiotic effect (PAE) induced
by ceftizoxime, ceftriaxone,
cefoxitin, ampicillin-sulbactam, and ticarcillin-clavulanate against selected isolates of Bacteroides
fragilis and B.
thetaiotaomicron. Anaerobe 8:295-299.
135. Aldridge,
K.E. and Sanders, C.V. 2002. Susceptibility trending of blood isolates of the Bacteroides
fragilis group over a 12-year period
to clindamycin, ampicillin-susbactam, cefoxitin, imipenem, and
metronidazole. Anaerobe 8:301-305.
136. Aldridge,
K.E., Ashcraft, D., O’Brien, M.,
and Sanders, C.V. 2003. Bacteremia due to Bacteroides fragilis group:
distribution of species, b-lactamase
production, and antimicrobial
susceptibility patterns.
Antimicrob. Agents Chemother.
47:148-153.
137. Ferris,
J.J., Marztaz, A., Aldridge, K.E. Fortenberry, D., Fidel, P.L., and Martin, D.H. 2004. Association of Atopobium
vaginae, a recently described
metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infectious
Diseases 4:5. http://www.biomedcentral.com/1471-2334/4/5.
138. Butt,
A.A., Aldridge, K.E., Sanders,
C.V. 2004. Infections related to the ingestion of seafood. Part I: viral and
bacterial infections. The LANCET Infectious Diseases 4:201-212.
139. Butt,
A.A., Aldridge, K.E., and
Sanders, C.V. 2004. Infection related to the ingestion of seafood. Part II:
parasitic infections and food safety. The LANCET Infectious Diseases 4:294-300.
140.
Aldridge, K.E. 2004. Commentary: Treatment of community
acquired methicillin-resistant Staphylococcus aureus. Ped Infect. Forum 6:4-5.
141. Welch, D.F. and Aldridge, K.E. 2005. Optimizing detection of group B strep from antepartum cultures. Infect. Med. 22:133-136.